In this episode, we explore Fragile X syndrome, the leading inherited cause of intellectual disability and a major genetic cause of autism, which arises from a specific mutation in the FMR1 gene that prevents the production of the essential protein FMRP. We examine the spectrum of disorders associated with this genetic change, including the neurodegenerative condition Fragile X-associated tremor/ataxia syndrome (FXTAS) and Fragile X-associated primary ovarian insufficiency (FXPOI), both of which affect carriers of the premutation. Finally, we discuss the evolving landscape of targeted treatments—ranging from mGluR5 antagonists to potential gene therapies—that aim to correct the underlying neurobiological deficits responsible for the condition.

In this episode, we explore placental insufficiency, a condition where the placenta fails to deliver adequate nutrients and oxygen, driving complications like fetal growth restriction (FGR) and preeclampsia. We discuss how Doppler velocimetry helps specialists time delivery to balance the risks of stillbirth against prematurity and examine the profound long-term health consequences for both mother and child, including increased risks of cardiovascular disease and neurodevelopmental impairment. Finally, we highlight the future of treatment, specifically emerging placental gene therapies that utilize IGF-1 to potentially repair placental function in utero.

In this episode we explore the complexities of Congenital Toxoplasmosis (CTX), a parasitic infection caused by Toxoplasma gondii that presents a unique clinical paradox: while the risk of transmitting the infection to the fetus increases as pregnancy progresses, the severity of fetal damage—such as hydrocephalus and intracranial calcifications—is highest when infection occurs in the first trimester. We examine the stark contrast in global public health strategies, comparing France’s mandatory monthly prenatal screening model against the US’s symptom-triggered approach, and how these policies impact patient outcomes. Finally, we break down the "gold standard" treatment protocols—including the use of spiramycin to prevent transmission and the pyrimethamine-sulfadiazine combination for infected fetuses and infants—and discuss the lifelong risks of delayed ocular sequelae like chorioretinitis, emphasizing why long-term monitoring is essential even for asymptomatic newborns.

In this episode, we explore Neurofibromatosis Type 1 (NF1), a multisystem genetic disorder affecting approximately 1 in 3,000 individuals that is driven by hyperactive Ras signaling due to the loss of the tumor suppressor protein neurofibromin. We examine the condition's diverse clinical spectrum, which ranges from hallmark skin manifestations like café-au-lait macules and neurofibromas to severe complications including malignant peripheral nerve sheath tumors, skeletal deformities, and cognitive impairments such as ADHD. The discussion highlights significant therapeutic milestones, such as the FDA approval of the MEK inhibitor selumetinib for inoperable plexiform neurofibromas, alongside emerging research into gene therapy and the profound impact of disease visibility and chronic itch on patient quality of life.

In this episode, we explore Tetralogy of Fallot, the most common cyanotic congenital heart defect, characterised by four cardinal anatomical anomalies including a ventricular septal defect and right ventricular outflow tract obstruction. We analyse the evolution of palliative strategies, highlighting evidence that right ventricular outflow tract stenting offers superior pulmonary artery growth and higher oxygen saturation compared to the traditional modified Blalock-Taussig shunt. The discussion weighs the surgical trade-offs between valve-sparing repair, which is associated with shorter intensive care stays and lower mortality, and transannular patching, which resolves obstruction but leads to chronic pulmonary regurgitation. Finally, we emphasise the critical role of lifelong surveillance using advanced cardiac MRI to monitor adult survivors for risks such as arrhythmias and right ventricular dysfunction.

In this episode, we examine anencephaly, a lethal neural tube defect where the fetal brain and skull fail to develop properly during the first month of pregnancy. We discuss the critical success of folic acid fortification in prevention, diagnostic indicators like the "Frog Eye" sign on ultrasound, and the complex ethical considerations surrounding palliative care and organ donation. Finally, we explore groundbreaking research into in utero gene editing that aims to correct genetic causes of the condition before birth.

In this episode, we examine Osteochondritis Dissecans (OCD) of the knee, an idiopathic condition characterized by subchondral bone necrosis that can lead to cartilage detachment and early osteoarthritis. We discuss the critical distinction between juvenile and adult forms, highlighting how lesion stability determined by MRI guides the choice between conservative management—such as rest and bracing—and surgical interventions like drilling, fixation, or cartilage restoration.

In this episode, we examine radiation proctitis, a condition affecting the rectum in patients undergoing pelvic radiotherapy for cancers such as prostate, cervical, and rectal malignancies. We distinguish between the acute phase, caused by direct inflammatory mucosal injury, and chronic radiation proctopathy (increasingly termed RAVE), which is characterised by progressive ischaemia, fibrosis, and fragile blood vessels known as telangiectasias. Finally, we explore the management spectrum, ranging from supportive care like sucralfate enemas and low-residue diets to advanced interventions such as Argon Plasma Coagulation (APC) and Hyperbaric Oxygen Therapy (HBOT) for refractory bleeding.

In this episode, we explore Chronic Kidney Disease-Associated Pruritus (CKD-aP), a debilitating neuro-immune condition affecting up to 70% of dialysis patients that significantly disrupts sleep and quality of life. We examine the complex pathophysiology behind this "uremic itch"—involving opioid system imbalance and systemic inflammation—and review the shift from ineffective antihistamines to targeted management strategies, including gabapentinoids and the novel kappa-opioid receptor agonist, difelikefalin.

In this episode, we examine Coarctation of the Aorta (CoA), a congenital narrowing typically found near the ligamentum arteriosus, discussing diagnostic hallmarks like blood pressure discrepancies between extremities and the use of multimodal imaging. We explore the evolution of treatment strategies, comparing surgical techniques—such as extended end-to-end anastomosis—against endovascular options like stenting, which has become the preferred therapy for adolescents and adults. Finally, we highlight the critical need for lifelong surveillance to manage long-term complications, including persistent hypertension, re-coarctation, and the increased risk of aortic or intracranial aneurysms.